Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

• Status: Completed
• Trial end date: 2019-01-24
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate if a treatment the investigators call iCOMMIT is effective at helping smokers with schizophrenia stop smoking. iCOMMIT is a smoking cessation treatment that combines mobile technology with behavioral strategies, counseling, and medications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Treatments: Bupropion; Nicotine

Criteria

Inclusion Criteria:

• Currently smoke at least ten cigarettes a day

• Have been smoking for at least one year

• Meet criteria for schizophrenia, schizoaffective disorder, or another psychotic disorder based on structured clinical interview

• Can speak and write fluent conversational English

• Are between 18 and 70 years of age

• Are willing to make a smoking cessation attempt

• Score 26 or higher on the Montreal Cognitive Assessment

Exclusion Criteria:

• Have a history of myocardial infarction in the past 6 months

• Have a contraindication to NRT with no medical clearance from the primary care provider or study physician

• Use and unwillingness to stop use of other forms of nicotine such as cigars, pipes, or chewing tobacco

• Are pregnant

• Meet criteria for a current manic episode based on structured clinical interview

• Are currently enrolled in another smoking cessation trial

• Are currently imprisoned or in psychiatric hospitalization